The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Efficacy and safety of continuous vs interrupted ixekizumab treatment in patients with plaque psoriasis: Results from a phase III trial
|
A multicenter, randomized, phase III trial (NCT03364309) assessed ixekizumab vs placebo in patients with moderate-to-severe plaque psoriasis in China.1 Following 12-week induction, ixekizumab responders (n = 289) were re-randomized 2:1 to ixekizumab Q4W maintenance (IXE/IXE group; n = 192) or placebo Q4W (IXE/PBO group; n = 97), with patients who had disease worsening switching to ixekizumab Q4W (IXE/PBO + IXEQ4W group). Results were published in Advances in Therapy by Gao et al.1 |
| Key learnings |
| At Week 60, in the IXE/IXE group, PASI 75, PASI 90, PASI 100, sPGA (0,1), and sPGA (0) response rates were 75.0%, 70.3%, 53.1%, 68.2%, and 53.1%, respectively, compared with 6.2%, 3.1%, 0%, 2.1%, and 0%, respectively, in the IXE/PBO group (all p < 0.001). |
| In the IXE/PBO group, 90.7% of patients experienced disease relapse. After 24 weeks of re-treatment, patients in the IXE/PBO + IXEQ4W group had PASI 75 and sPGA (0,1) response rates of 97.2% and 76.4%, respectively. |
| No new safety signals were observed, and AEs were comparable between continuous treatment and re-treatment patients. |
| Results from this trial highlight the benefit of continuous ixekizumab treatment through 60 weeks in patients with moderate-to-severe plaque psoriasis. While the majority of patients who stopped ixekizumab treatment relapsed, re-treatment successfully restored response rates in most patients. |
Abbreviations: AE, adverse event; IXE, ixekizumab; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q4W, every 4 weeks; sPGA, static Physician’s Global Assessment.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
